Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Claudepierre

Showing results (31-40 of 154) with videos related to

Pageof 16
Sort By:
Joint Bone Spine|June 7, 2015
MRI in axial spondyloarthritis: From light to shadow?Daniel Wendling, Pascal Claudepierre, Thao Pham, et al.
Joint Bone Spine|February 15, 2016
TNFα antagonist therapy in axial spondyloarthritis: Can we do better?Clément Prati, Pascal Claudepierre, Philippe Goupille, et al.
Joint Bone Spine|July 31, 2012
Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name?Pascal Claudepierre, Daniel Wendling, Maxime Breban, et al.
Presse Medicale (Paris, France : 1983)|October 10, 2003
[Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies]Daniel Wendling, Pascal Claudepierre, Anne Lohse, et al.
The Journal of Rheumatology|January 5, 2005
Poorly and well controlled spondyloarthropathies: a comparison of 2 groups of patientsOwonayo Oniankitan, Nathalie Ranaivo, Laurence Carton, et al.
Joint Bone Spine|August 4, 2012
Non-radiographic spondyloarthritis: a theoretical concept or a real entity?Daniel Wendling, Clément Prati, Pascal Claudepierre, et al.
Joint Bone Spine|September 10, 2021
Tight control and treat-to-target in axial spondyloarthritis. Where are we?Daniel Wendling, Pascal Claudepierre, Philippe Goupille, et al.
RMD Open|January 4, 2023
Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)Laura Pina Vegas, Léa Hoisnard, Léa Bastard, et al.
Joint Bone Spine|March 31, 2012
Spondylarthritis and monoclonal gammopathyDaniel Wendling, Clément Prati, Jean-Marie Berthelot, et al.
RMD Open|March 14, 2024
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)Léa Bastard, Pascal Claudepierre, Laetitia Penso, et al.
Pageof 16

Showing results (31-40 of 154) with videos related to

Sort By:
Pageof 16
Joint Bone Spine|June 7, 2015
MRI in axial spondyloarthritis: From light to shadow?Daniel Wendling, Pascal Claudepierre, Thao Pham, et al.
Joint Bone Spine|February 15, 2016
TNFα antagonist therapy in axial spondyloarthritis: Can we do better?Clément Prati, Pascal Claudepierre, Philippe Goupille, et al.
Joint Bone Spine|July 31, 2012
Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name?Pascal Claudepierre, Daniel Wendling, Maxime Breban, et al.
Presse Medicale (Paris, France : 1983)|October 10, 2003
[Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies]Daniel Wendling, Pascal Claudepierre, Anne Lohse, et al.
The Journal of Rheumatology|January 5, 2005
Poorly and well controlled spondyloarthropathies: a comparison of 2 groups of patientsOwonayo Oniankitan, Nathalie Ranaivo, Laurence Carton, et al.
Joint Bone Spine|August 4, 2012
Non-radiographic spondyloarthritis: a theoretical concept or a real entity?Daniel Wendling, Clément Prati, Pascal Claudepierre, et al.
Joint Bone Spine|September 10, 2021
Tight control and treat-to-target in axial spondyloarthritis. Where are we?Daniel Wendling, Pascal Claudepierre, Philippe Goupille, et al.
RMD Open|January 4, 2023
Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)Laura Pina Vegas, Léa Hoisnard, Léa Bastard, et al.
Joint Bone Spine|March 31, 2012
Spondylarthritis and monoclonal gammopathyDaniel Wendling, Clément Prati, Jean-Marie Berthelot, et al.
RMD Open|March 14, 2024
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)Léa Bastard, Pascal Claudepierre, Laetitia Penso, et al.
Pageof 16